Case report: Dysphonia associated with high-dose cytarabine therapy
Cytarabine is widely used in the treatment of hematological malignancies. Its common toxicities include myelosuppression and gastrointestinal disturbances. Additionally, it can cause central nervous system (CNS) symptoms, which include hoarseness, ataxic tremor, ataxic gait, nystagmus, dysmetria, an...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1518298/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585026458353664 |
|---|---|
| author | Ling Ma Niya Huang Haixi Zhang Jia Liu Zhiqing Zhang |
| author_facet | Ling Ma Niya Huang Haixi Zhang Jia Liu Zhiqing Zhang |
| author_sort | Ling Ma |
| collection | DOAJ |
| description | Cytarabine is widely used in the treatment of hematological malignancies. Its common toxicities include myelosuppression and gastrointestinal disturbances. Additionally, it can cause central nervous system (CNS) symptoms, which include hoarseness, ataxic tremor, ataxic gait, nystagmus, dysmetria, and dysdiadochokinesia. In this article, we present the first case report of dysphonia, absent of CNS symptoms, induced by high-dose cytarabine (HiDAC) in a patient with acute myeloid leukemia. The patient’s voice began to change 3 days following the first cycle of HiDAC chemotherapy, and dysphonia recurred upon the reintroduction of HiDAC. To rule out other potential causes, a thorough examination and detailed medical history review were conducted, excluding factors such as vocal abuse, infection, effects of other medications, and underlying diseases as contributors to the dysphonia. The patient was diagnosed with HiDAC-induced dysphonia. This toxic effect was self-limiting, and the patient recovered in 10–15 days. Chemotherapy-induced dysphonia is a rarely reported and easily overlooked side effect. This adverse reaction is typically temporary and non-life-threatening; however, it substantially diminishes quality of life and may occasionally necessitate the discontinuation or postponement of chemotherapy. Physicians should be aware of this complication when administering chemotherapeutic agents. |
| format | Article |
| id | doaj-art-cd7fedc5a38f4c44b62a1728230fec9f |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-cd7fedc5a38f4c44b62a1728230fec9f2025-01-27T06:40:29ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.15182981518298Case report: Dysphonia associated with high-dose cytarabine therapyLing Ma0Niya Huang1Haixi Zhang2Jia Liu3Zhiqing Zhang4Department of Clinical Pharmacy, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, ChinaDepartment of Clinical Pharmacy, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, ChinaDepartment of Hematology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, ChinaDepartment of Clinical Pharmacy, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, ChinaDepartment of Clinical Pharmacy, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, ChinaCytarabine is widely used in the treatment of hematological malignancies. Its common toxicities include myelosuppression and gastrointestinal disturbances. Additionally, it can cause central nervous system (CNS) symptoms, which include hoarseness, ataxic tremor, ataxic gait, nystagmus, dysmetria, and dysdiadochokinesia. In this article, we present the first case report of dysphonia, absent of CNS symptoms, induced by high-dose cytarabine (HiDAC) in a patient with acute myeloid leukemia. The patient’s voice began to change 3 days following the first cycle of HiDAC chemotherapy, and dysphonia recurred upon the reintroduction of HiDAC. To rule out other potential causes, a thorough examination and detailed medical history review were conducted, excluding factors such as vocal abuse, infection, effects of other medications, and underlying diseases as contributors to the dysphonia. The patient was diagnosed with HiDAC-induced dysphonia. This toxic effect was self-limiting, and the patient recovered in 10–15 days. Chemotherapy-induced dysphonia is a rarely reported and easily overlooked side effect. This adverse reaction is typically temporary and non-life-threatening; however, it substantially diminishes quality of life and may occasionally necessitate the discontinuation or postponement of chemotherapy. Physicians should be aware of this complication when administering chemotherapeutic agents.https://www.frontiersin.org/articles/10.3389/fphar.2025.1518298/fullacute myeloid leukemiadysphoniahigh-dose cytarabineadverse reactioncase report |
| spellingShingle | Ling Ma Niya Huang Haixi Zhang Jia Liu Zhiqing Zhang Case report: Dysphonia associated with high-dose cytarabine therapy Frontiers in Pharmacology acute myeloid leukemia dysphonia high-dose cytarabine adverse reaction case report |
| title | Case report: Dysphonia associated with high-dose cytarabine therapy |
| title_full | Case report: Dysphonia associated with high-dose cytarabine therapy |
| title_fullStr | Case report: Dysphonia associated with high-dose cytarabine therapy |
| title_full_unstemmed | Case report: Dysphonia associated with high-dose cytarabine therapy |
| title_short | Case report: Dysphonia associated with high-dose cytarabine therapy |
| title_sort | case report dysphonia associated with high dose cytarabine therapy |
| topic | acute myeloid leukemia dysphonia high-dose cytarabine adverse reaction case report |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1518298/full |
| work_keys_str_mv | AT lingma casereportdysphoniaassociatedwithhighdosecytarabinetherapy AT niyahuang casereportdysphoniaassociatedwithhighdosecytarabinetherapy AT haixizhang casereportdysphoniaassociatedwithhighdosecytarabinetherapy AT jialiu casereportdysphoniaassociatedwithhighdosecytarabinetherapy AT zhiqingzhang casereportdysphoniaassociatedwithhighdosecytarabinetherapy |